Monday, May 22, 2023

歯科矯正治療後の歯の正しい位置を保つための最適な方法は何か？ 要点 - エビデンスの信頼性が低いため、歯の位置を固定（保定）するための最善の方法については、明確な結論を出すことはできない。 - より適切に計画された研究が必要である。少なくとも2年を超える期間における歯の位置の安定性、保定装置（リテーナー）の耐久性、患者の満足度、およびリテーナーによる有害事象（う蝕や歯周病など）の評価をする必要がある。 論点 歯科矯正治療後に、歯の位置が後戻りしてしまうことがある。矯正歯科医は、治療後の歯の位置を保つ（保定する）ために、さまざまな方法を用いて、後戻りを防止する。保定装置（リテーナー）は、通常、ワイヤーや透明なプラスチック等で個人に合わせて製作され、取り外しのできないもの（固定式リテーナー）または取り外しが可能なもの（可撤式リテーナー）に分類される。可撤式リテーナーは、常時または任意の時間での装着が可能である。リテーナーは、歯列全体や歯の周囲、または歯の裏側に装着される。場合により、歯と歯の間を削る処置（歯間削合）や、歯と歯肉をつなぐ線維を切断する処置（歯周靭帯の切離）などの補助的な処置が行われることもある。 何が知りたかったのか？ 歯科矯正治療後の歯の位置を保つための最適な方法と、有害事象の有無について調査することを試みた。 何を行ったのか？ 歯科矯正治療後に使用した異なる種類のリ...

It is with great sadness that we mark the passing of Hyeong Sik Ahn, Director of Cochrane Korea, Professor at the Department of Preventive Medicine, and former Dean of the Graduate School of Public Health at Korea University.

Professor Ahn's enduring relationship with Cochrane, spanning over twenty years, began when he attended his first Cochrane Colloquium in 2002. This initial gathering in Norway fueled his determination to introduce Cochrane principles in Korea. In 2007, Professor Ahn led the establishment of the Korean Branch of the Australasian Cochrane Center. Two years later, Cochrane Korea was officially inaugurated at Korea University as a geographical group of Cochrane.

Beyond his Cochrane-related activities, Professor Ahn organized the 8th Guidelines International Network Conference in the summer of 2011, themed "Linking Evidence, Policy, and Practice," marking the first time the conference was held in Asia. In 2014, he authored an influential article published in the New England Journal of Medicine titled "Korea's Thyroid Cancer 'Epidemic' – Screening and Overdiagnosis." This article highlighted Professor Ahn's determination to address overdiagnosis, particularly within the Korean healthcare system.

One of the highlights of Professor Ahn's academic career was hosting the 24th Cochrane Colloquium in the fall of 2016 in Seoul, where colleagues and researchers from around the world gathered for a successful conference that the Cochrane Korea team fondly remembers. In 2015, he spearheaded the implementation of the Choosing Wisely Korea campaign, aimed at reducing unnecessary medical tests and treatments in the country. By 2022, the campaign had gained endorsement from twenty-seven Korean medical societies.

"Professor Ahn played a pivotal role in establishing Evidence-Based Medicine in Korea," says Catherine Spencer, CEO of Cochrane. "To the fortunate students and colleagues who knew him, his passing represents an immeasurable loss. He will be deeply missed."

Professor Hyun Jung Kim, who served as co-director alongside Professor Ahn, will now assume the role of Director of Cochrane Korea, carrying forward Professor Ahn's inspiring legacy.

• Visit the Cochrane Korea website

 

 

 

Friday, May 19, 2023

Cochrane, a global independent network of researchers, professionals, patients, carers, and health enthusiasts, proudly announces the publication of its latest Special Collection titled "Cochrane at 30: what our 30th year can tell us about the future." 

In an era where access to health evidence has expanded, the risk of misinterpreting complex content has grown, while the likelihood of individuals obtaining a comprehensive and balanced understanding has diminished. Cochrane's role in providing accessible, credible information to support informed decision-making has never been more critical in improving global health.

At the heart of Cochrane's mission is the collaborative production of trustworthy health information devoid of commercial sponsorship and conflicts of interest. This commitment enables the generation of authoritative and reliable evidence, unconstrained by commercial and financial interests. Cochrane's systematic reviews, which gather and analyze the best available evidence, are recognized globally as the gold standard for reliable and high-quality information.

The need for Cochrane's work is even greater than it was when we started in 1993. In an era where access to health evidence has expanded, the risk of misinterpreting complex content has grown, while the likelihood of individuals obtaining a comprehensive and balanced understanding has diminished. Cochrane's role in providing accessible, credible information to support informed decision-making has never been more critical in improving global health.

To commemorate Cochrane's 30th anniversary, we have curated a collection of Cochrane Reviews that exemplify the enduring mission and innovative approaches taken by our organization. This special collection underscores the future of Cochrane, built upon its rich history of methodological diversity and unwavering dedication to meeting user needs.

• View the Cochrane Library Special Collection

 

 

Friday, May 19, 2023

肝移植後の成人に対する運動介入 背景 肝移植を受けた場合、身体活動レベルが低下する傾向にある。しかし、心臓や肺の病気、高血圧、2型糖尿病、認知症、非アルコール性脂肪性肝疾患（肝臓に脂肪が蓄積して起こる病気）、がん、およびその他の急速に発症し、生命を脅かす可能性のある病気の発症を防ぐための運動介入の有益性と有害性については、まだ十分に研究されていない。 何を調べようとしたのか？ 肝移植後の成人における運動の有益性と有害性を明らかにしようとした 何を行ったのか？ 肝移植のレシピエント（移植を受ける患者）を対象に、あらゆる種類の運動について、運動を行わなかった場合、偽の介入を行った場合、および他の種類の運動を行った場合と比較した、適切にデザインされた臨床試験について、医学データベースの検索を行った。 何が見つかったのか？ 合計241人の参加者を対象とした3件のランダム化（臨床）比較試験が見つかり、試験が終了できていた参加者は199人であった。ランダム化比較試験とは、参加者を実験群と対照群に無作為に割り付ける研究である。研究は、米国、スペイン、およびトルコで実施されていた。運動の期間は、2か月、6か月、または10か月と異なっていた。すべての研究は、運動療法に基づいた介入を通常の治療と比較したものであった。すべての研究は、肝移植を受けた成人を対象としていた。3件の研究では、さまざまな運動介...

Specifications: Permanent – Full Time (Hybrid Role, 3 days office and 2 days WFH)
Salary: £55,257 (Paid in DKK, as per market exchange rate) per annum
Location: Copenhagen, Denmark
Directorate: Publishing & Technology
Closing date: 7 June 2023

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

As development team lead, you will manage an Agile/Scrum software development team (3 developers, 1 test engineer) who develop web applications that accelerate the production of systematic reviews of health evidence. You will support the team in their work, coordinate with product owners on timelines, and contribute to software testing within the team as needed to ensure sprint goals are met.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everting we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect:  

• An opportunity to truly impact health globally  
• A flexible work environment  
• A comprehensive onboarding experiences
• An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 7 June 2023.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Read our Recruitment Privacy Statement

Tuesday, May 23, 2023 Category: Jobs

ホルモン剤による避妊をしていない人と比較した、ホルモン剤による避妊をしている人が新型コロナウイルス感染症(COVID-19)にかかった時に血栓を発症する確率 論点 COVID-19になった人の、心臓発作や脳卒中を含む血栓の発生やその他の重篤な結果に対するホルモン剤による避妊法の影響に関するエビデンスを検討した。エストロゲンとプロゲスチンの両方を含む避妊薬を服用している人と、ホルモン剤を使用しない避妊をしている人、プロゲスチンだけを含む避妊薬を服用している人を比較検討したいと考えた。該当する研究は5件しか見つからなかった。 背景 ホルモン剤による避妊、特にエストロゲンを含む避妊薬の使用は、足や肺に血栓ができる可能性を高めたり、脳卒中になる可能性を高めたりすることがある。また、COVID-19の発症により、足や肺に血栓ができることも確認されている。ホルモン剤による避妊をしている人がCOVID-19になった場合、血栓ができる可能性が高いかどうかはわかっていない。ホルモン剤による避妊をしている人がCOVID-19陽性になった場合、避妊薬の使用を止めるべきか、違う避妊法に切り替えるべきかを知ることができるよう、さらなる研究が必要である。 研究の特性 2022年3月までに発表された研究を対象とした。避妊をした人（特に、ホルモン配合剤のようにエストロゲンを含む避妊薬を使用した人）における、避妊...

医療従事者の職業性ストレスを軽減するための個人レベルの介入 要点 - ストレスの経験に注意を向ける（思考、感情、行動に注意を向けるなど）、またはストレスの経験から意識を遠ざける（運動する、リラックスするなど）個人レベルの介入は、介入後1年まで医療従事者のストレスを軽減する可能性がある。 - 個人レベルの介入を組み合わせることで、介入から2、3か月後まではストレスが軽減される可能性がある。 - 個人レベルで仕事関連の危険因子に焦点を当てた介入がストレスに効果があるかどうかはわからない。 ストレスとは何か？ 現在のところ、（仕事に関連した）ストレスの明確な定義はない。このレビューは、ストレスレベルが低い医療従事者から、 うつ状態や不安につながるかもしれないが、必ずしもうつ状態や不安を生じるとは限らない、中等度の苦痛や燃え尽き症候群の医療従事者についてのものである。ストレスを抱える人は、頭痛や筋肉の緊張、痛みといった身体的症状だけでなく、集中力の低下といった精神的症状も経験する。また、行動的な問題（他人との衝突など）や情緒的な問題（情緒不安定など）を抱えることもある。 医療従事者のストレスに対して何ができるか？ 医療従事者のストレスは、組織レベルだけでなく、個人レベルでも取り組むことができる。個人レベルでのストレス管理介入は、以下を目的としている： - 例えば、認知行動療法や対処技能訓...

新生児の気管内挿管にビデオ補助（ビデオ喉頭鏡）を使用することは、手技の成功と安全性を高めるか？ 要点 ビデオ喉頭鏡の使用は、初回の気管内挿管成功率を高め、ケア提供者が病気の新生児の気管内挿管を施行する回数をわずかに減らす結果になるかもしれないが、気管内挿管にかかる時間を短縮するわけではない。 ビデオ喉頭鏡の使用では、挿管時の新生児の気道の傷がわずかに少ないと思われる。 さまざまな診療領域で、さまざまなケア提供者が配置を行う場合のビデオ喉頭鏡の役割を理解するために、より良い研究が必要である。 何が問題なのか？ 新生児の100人に1人は、呼吸が困難な場合、口か鼻に呼吸用チューブを挿入して（気管内挿管）命をつなぐ必要がある。新生児は口や気道が小さいため、直接喉頭鏡を使って（ビデオなしで）呼吸用チューブを挿入するのは難しいかもしれないし、すべてのケア提供者が経験を積んでいるわけではない。 ビデオ喉頭鏡法とは何か？ ビデオで気道を見ながら気管内挿管を行うことを、ビデオ喉頭鏡法という。そうすることで、呼吸チューブの挿入がより簡単で安全になる。これはまた、トレーニングを受けている人がこの救命技術を習得する際にも役立つだろう。 何を調べようとしたのか？ 生後0日から28日の乳児を対象に、直接喉頭鏡法よりもビデオ喉頭鏡法の方が、呼吸チューブの挿入の成功と安全性が高まるかどうかを調べようとした。 何...

Thursday, May 11, 2023

Thursday, May 11, 2023

Stroke, heart disease, hypertension and peripheral vascular diseases are leading global causes of mortality and morbidity. As the population ages and these conditions become more common in low-income countries, the need for an integrated response has become increasingly clear.

The new Heart, Stroke and Circulation Thematic Group aims to bring together experts from across all four topics to foster collaboration between researchers in different fields while providing comprehensive reviews on cutting-edge topics related to stroke, heart disease, hypertension, and peripheral vascular diseases. 

A collaborative effort

Through this collaborative effort, it is hoped that progress toward a better understanding of these conditions can be accelerated while also providing improved patient care.

The Heart, Stroke and Circulation Group has 708 relevant Cochrane reviews; 216 of which have been used over 1,000 times each and some of which have been used over 5,000 times. 

Professor Mead explained: “Multimorbidity prevalence will increase with an ageing global population and we know that different vascular diseases coexist in the same person. We hope that through our new thematic group, we will be able collective expertise and knowledge, create more comprehensive reviews, which will be of benefit to patients living with vascular disease, and also those making treatment and policy decisions in this area.”

Covering a broader range of topics in greater depth

As populations age and these conditions become more prevalent in low-income countries, the need to work together becomes increasingly important. 

This new thematic group was formed to reduce topic overlap between the four areas of research and to improve time-to-publication by sharing collective expertise and knowledge and collaborating with experts around the world. By combining forces, they will be able to provide reviews that cover a broad range of topics with greater depth. The aim is to benefit experts looking for information but, equally as importantly, patients who may have a combination of diseases or issues that cross over between multiple disciplines. 

Alex Todhunter-Brown continues: "Management of heart disease, stroke, hypertension, and peripheral vascular diseases is a global challenge that requires an integrated approach. The Heart, Stroke and Circulation Thematic Group is an alliance of experts, united by a common goal to generate evidence to support the best ways of prevention, treatment and rehabilitation of these conditions. Our goal is to improve outcomes for people with these conditions – we can do this by ensuring that we have robust, reliable evidence about effective treatments and rehabilitation strategies. Working together, we can make a difference to people affected by heart, stroke and circulation problems."

• Learn more about Cochrane Heart, Stroke and Circulation and get involved

Wednesday, May 10, 2023

  Characterised by close collaboration and cross-disciplinary expertise, Cochrane’s new Person-Centred Care, Health Systems and Public Health Thematic Group is led by Rebecca Ryan (CCC, La Trobe University Australia), Luke Wolfenden (CPH, University of Newcastle, Australia), Simon Lewin (EPOC, Norwegian University of Science and Technology) and Sasha Shepperd (EPOC, University of Oxford), the new Group has its sights set on bringing quantitative, qualitative and mixed methods expertise to evidence applied across diverse clinical areas, populations and contexts.   ‘We know the UN Sustainable Development Goals (SDGs) highlight the interconnectedness between health and public health systems and personal, social and environmental contexts,’ Rebecca Ryan explains. ‘But to date Cochrane hasn’t been well placed to engage with this cross-cutting agenda. Establishing this Thematic Group offers a really timely and promising opportunity to begin doing so. We are really looking forward to working together on this.’

‘With our longstanding shared interests in methods, topics and complex reviews, we have enjoyed the benefits of close collaboration for many years. We now want to enable Cochrane to take forward evidence syntheses that span these complex areas and contribute to the delivery of the SDGs and improvement of global health outcomes.’

‘Working more closely as a coordinated Thematic Group will enable cross-cutting priority topics to be identified, along with overlapping areas where research waste might be reduced. There will also be scope to explore effective and efficient ways of providing content input through new Evidence Synthesis Units and the Central Editorial Service. There are so many possibilities.’

Person-Centred Care

Person-centred approaches are a key part of ensuring that health and public health systems interventions, and their implementation strategies, meet the needs of patients, family members, carers and other stakeholders by identifying priority topics and outcomes that are mutually beneficial.

‘Person-centred approaches can lead to more sustainable and resilient services and systems that are better able to meet individual and community needs. They promote engagement, empowerment and equity and are increasingly recognised as necessary for safe, high-performing health systems,’ Rebecca says. ‘There are many examples of improvements where health and public health systems have adopted a person- centred approach. On the other hand, when health care organisation and delivery is less focused on people we know the outcomes can be dire – for example leading to antibiotic resistance due to poor prescribing , increased medication errors, fragmented care and risks to patient safety, increased maternal mortality, and inappropriate and unresponsive end of life care.’

Bringing together evidence on person-centred care and evidence from the fields of health and public health systems will contribute to ensuring that Cochrane evidence addresses these critical issues and meets the needs of diverse communities around the world.’

Health Systems and Public Health

The COVID-19 pandemic continues to highlight the urgent need for resilient health and public health systems that effectively engage people within and across communities. In response, the Person-Centred Care, Health Systems and Public Health Thematic Group will support the integration of evidence-based interventions into health and public health systems to improve outcomes for patients and communities globally. To do so, the Group will draw on a range of disciplines including health services research, behavioral and implementation sciences, stakeholder engagement and participatory methods, qualitative research, and quality improvement.

‘A health system includes the policies, organizations and activities that have the primary purpose of promoting, restoring or maintaining the health and wellbeing of individuals and the public,’ Rebecca explains. ‘They are complex structures spanning local, national and global contexts and involve a multiplicity of delivery platforms – so for example health facilities of all sorts, schools, communities and households - and an even wider range of service users and other stakeholders.’

‘We know interventions focused on health and public health systems can have substantial effects on peoples’ lives. We need high quality evidence to identify effective health or public health policies, programmes and services and maximise their benefits. We also need evidence-based strategies to support their implementation in feasible ways that meet the needs of consumers and key stakeholders.’

Global scope, focus on low- and middle-income countries (LMICs)

Collectively, this new Thematic Group brings over two decades of substantial experience working with LMIC-based partners to identify priority topics, conduct syntheses, disseminate key findings and strengthen capacity.

‘We look forward to building on the strong representation of LMIC-based editors and other partners in the months and years ahead,’ says EPOC’s Simon Lewin. ‘For example, our group currently has five LMIC-based editors and associate editors. We also have a number of strategies in place that will help to ensure we support the development and use of evidence relevant to LMICs. Our Internal Reference Group and International Advisory Panel will include strong participation from LMIC-based partners, and we will work closely with LMIC-based Cochrane geographic entities, several of which have expressed support for this Thematic Group.’

‘We also look forward to engaging with key organisations, such as the WHO HQ and relevant WHO regional offices, to identify priority synthesis topics for LMIC settings. Our knowledge translation approach will consistently consider ways of reaching LMIC-based policy users and other stakeholders.’

Next steps

‘As one of the first Thematic Groups, we plan to dedicate time to engaging with the wider Cochrane community to understand our role and set priorities that align with important global health topics’, Rebecca says. ‘We will also build on our relationships with funders across our geographic contexts and topic areas to explore funding opportunities and options.’‘We have a real interest in further developing and extending our methods of working with consumers and other stakeholders so that we can build expertise and capacity in a wider range of approaches and activities. Activities include active involvement in priority setting for research and review topics, community engagement to inform sharing of research findings directly with policymakers, and co-production of research including co-authoring Cochrane reviews. We intend that these kinds of activities will continue, alongside new and evolving opportunities to contribute to Cochrane and evidence synthesis activities.

• Learn more about Person Centred Care, Health Systems and Public Health and get involved

Wednesday, May 10, 2023

抗うつ薬は慢性的な痛みの治療にどの程度有効であり、また有害事象を引き起こすか？ 要点 ・信頼性のある効果を示した抗うつ薬はデュロキセチンのみであった。標準的な用量（60mg）で有効性が認められ、それ以上の用量を使用することの有益性はなかった。 ・抗うつ薬の有害事象については、データが非常に不足していたため、不明であった。そのため、今後の研究によって対応していく必要がある。 ・慢性疼痛に対しては、他の抗うつ薬を投与する前に、まず標準用量のデュロキセチンを検討してもよいと思われる。 ・個人に合わせたアプローチを行うことが重要である。痛みは非常に個人的な感覚であり、エビデンスが決定的でないか、あるいは得られていない場合でも、特定の薬剤が有効である可能性がある。今後の研究では、抗うつ薬の有害事象に焦点を当て、より長期間の研究を行う必要がある。 慢性的な痛み（慢性疼痛）とは何か？ 慢性疼痛とは、3か月以上続く痛みのことである。世界の3分の1以上の人口が慢性疼痛を経験している。慢性疼痛は、気分や幸福感、または仕事や日常業務の遂行能力に影響を与えることが多い。 抗うつ薬は慢性疼痛に対してどのように作用するのか？ 抗うつ薬は、元来うつ病を治療するために開発された薬である。抗うつ薬の種類によって作用をもたらす仕組み（作用機序）は異なり、同様の作用機序を持つ抗うつ薬はいくつかの種類にまとめられている...

• Largest ever investigation into antidepressants used for chronic pain shows insufficient evidence to determine how effective or harmful they may be.
• Study reviewed commonly prescribed medications including amitriptyline, duloxetine, fluoxetine, citalopram, paroxetine, and sertraline.
• One third of people globally are living with long-term pain with many prescribed antidepressants to relieve symptoms.

Most antidepressants used for chronic pain are being prescribed with “insufficient” evidence of their effectiveness, scientists have warned.

A major investigation into medications used to manage long-term pain found that harms of many of the commonly recommended drugs have not been well studied.

The Cochrane review, led by scientists from several UK universities including Southampton and Newcastle, examined 176 trials consisting of nearly 30,000 patients involved in assessments which prescribed antidepressants for chronic pain.

Among the drugs studied were amitriptyline, fluoxetine, citalopram, paroxetine, sertraline, and duloxetine – with only the latter showing reliable evidence for pain relief. One third of people globally are living with chronic pain, World Health Organisation data shows, with many prescribed antidepressants for relieving symptoms.

Lead author Professor Tamar Pincus from the University of Southampton said: “This is a global public health concern. Chronic pain is a problem for millions who are prescribed antidepressants without sufficient scientific proof they help, nor an understanding of the long-term impact on health.

“Our review found no reliable evidence for the long-term efficacy of any antidepressant, and no reliable evidence for their safety for chronic pain at any point. Though we did find that duloxetine provided short-term pain relief for patients we studied, we remain concerned about its possible long-term harm due to the gaps in current evidence.”

Amitriptyline is one of the most commonly prescribed antidepressants for pain management worldwide. In the last 12 months, around ten million prescriptions were given to patients in England at the 10mg dose recommended for pain. By comparison, five million prescriptions were given at the higher doses recommended for depression.

For duloxetine, three and a half million prescriptions were dispensed in England, but the recommended doses do not currently differ between conditions.

The two-year Cochrane study was the largest ever assessment of antidepressants recommended by leading bodies including the UK’s National Institute for Health and Care Excellence (NICE) and the Food and Drug Administration (FDA) in the USA.

Statistician Gavin Stewart, review co-author from Newcastle University, said: “We are calling on governing health bodies NICE and the FDA to update their guidelines to reflect the new scientific evidence, and on funders to stop supporting small and flawed trials. Evidence synthesis is often complex and nuanced but the evidence underpinning the use of these treatments is not equivalent, so current treatment modalities are hard to justify.”

The review revealed that duloxetine was consistently the highest-rated medication and was equally as effective for fibromyalgia, musculoskeletal, and neuropathic pain conditions.

Other results showed:

• Standard doses of duloxetine are as successful for reducing pain as higher quantities.
• Milnacipran was also effective at reducing pain, but scientists are not as confident as duloxetine due to fewer studies with fewer people.

Prof Tamar Pincus added: “We simply cannot tell about other antidepressants because sufficiently good studies are not available – but it does not mean that people should stop taking prescribed medication without consulting their GP.”

Scientists responsible for the review, funded by the NIHR’s Health Technology Assessment programme, were from the universities of Southampton, Newcastle, Bristol, UCL, Bath, and Keele, alongside Oxford University Hospital.

The team assessed the trials using a statistical method that enables researchers to combine data from relevant studies to estimate the effects of different drugs, which have not been compared directly in individual trials.

University of Southampton researcher Dr Hollie Birkinshaw said: “Though previous investigations show that some antidepressants might relieve pain, there has never been a comprehensive study examining all medications across all chronic conditions – until now.

“The only reliable evidence is for duloxetine. Adopting a person-centred approach is critical to treatment and, when patients and clinicians decide together to try antidepressants, they should start from the drug for which there is good evidence.”

• Read the plain language summary and full Cochrane Review

Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta‐analysis. Cochrane Database of Systematic Reviews 2023, Issue 5. Art. No.: CD014682. DOI: 10.1002/14651858.CD014682.pub2.

Wednesday, May 10, 2023

A  full-time position as a Postdoc is vacant at Cochrane Denmark and at the Centre for Evidence-Based Medicine Odense (CEBMO), Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark (SDU).

Apply by 1 July 2023

The position is limited to two years with the possibility of extension by up to a maximum of two years, starting in September 2023 (negotiable).

The position involves research (50%), pre-graduate and postgraduate guidance and teaching (40%) and administration (10%).

Research tasks
The position as a postdoc consists of research, teaching, professional development, and guidance in Evidence-Based Medicine.

The centre’s main research topics are bias in clinical research, conflicts of interest, de-implementation, and medical devices. The centre is responsible for a pre-graduate course in evidence-based medicine for medical students, and postgraduate courses (e.g., PhD courses). Furthermore, the centre supports Cochrane authors and runs a methodological consultancy service for clinical researchers, e.g., when conducting systematic reviews.

We expect you to have a relevant academic degree (PhD level) and a research interest in evidence-based medicine and clinical research methodology.

The post involves responsibility for a primary project on exploring the concept of minimally relevant degree of bias in randomized trials.

Expectations of qualifications
The applicant must have a Ph.D.-degree and documented research experience in one or more of the following areas/fields:

• Evidence-based medicine
• Research methodology
• Clinical minimally relevant difference
• Meta-epidemiology

Potential applicants must be postdoc-qualified in accordance with Ministerial Order on Job Structure for Academic Staff at Universities.

Contact
For further information please contact the Head of Centre, OUH/SDU, Asbjørn Hróbjartsson, phone 24792553/ e-mail: ahrobjartsson@health.sdu.dk or the Head of  the Department of Clinical Research Kirsten Ohm Kyvik, phone: 6011 3046/ e-mail: KKyvik@health.sdu.dk

Conditions of employment
The Recruitment/Hiring takes place in accordance with the agreement between the Ministry of Finance and the Central Organisation of the Academics.

Assessment of applicant will be done in accordance with the current/applicable university recruitment order. Applicants will be assessed by an expert committee, and applicant will be informed of their assessment by the university.

Applications – including the required attachments – must be sent electronically via the below-mentioned link “Apply online". Only online applications will be accepted and assessed. Attached files must be Adobe PDF or Word format. Each field in the application form can contain up to max. 10 MB.

Only applications written in English will be accepted for evaluation.

The application must include (as PDF- or docx-files):

• A motivation letter
• A CV
• Copies of certificates/diplomas including evidence of acquisition of a PhD degree or equivalent
• A complete and numbered list of publications
• The 3 scientific, peer-reviewed publications that the applicant wishes to be included in the assessment of his or her scientific qualifications. (Please note that one PDF or docx file must be attached for each publication).
• A research plan
• A teaching portfolio
• An explanation of other qualifications relevant to the position.

Incomplete applications, which do not meet the above-mentioned requirements, will not be assessed.

See also the faculty's guidance for applicants at the link below.

Applications may be shortlisted

The University wishes our staff to reflect the diversity of society and thus welcomes applications from all qualified candidates regardless of personal background.

Living and working in Denmark
Foreign applicants will be offered Danish language training as part of the employment. The International Staff Office (ISO) at SDU provides a variety of services for new employees, guests and people who are considering applying for a job at the University of Southern Denmark. Among other things, the staff answers questions concerning salary, taxation, housing and accompanying family.

Further Details

• Guide for applicants
• Apply by 1 July 2023

Tuesday, May 9, 2023 Category: Jobs

中低所得国における有害なアルコール使用削減のための介入策 このレビューの重要性 有害なアルコールの使用は、世界的な疾病負荷の主な原因の1つである。中低所得国では、有害なアルコールの使用が増加している。しかし、有害なアルコール使用を予防・治療するサービスは限られている。利用可能なサービス不足の一因は、有害なアルコール使用を減らすにはどのような介入アプローチが効果的なのか、また、こうしたアプローチが低資源の環境で実行可能で受け入れられやすいかどうかについての情報が限られていることである。有害なアルコール使用による身体的、心理的、社会的負荷を防ぐためには、アルコールに関連した害を減らすための効果的な介入が利用できることが重要である。 本レビューの目的は何か？ このレビューの目的は、低・中所得国において、心理社会的・薬理学的介入が有害なアルコール使用を減らすことができるかどうかについてのエビデンスをまとめることである。また、治療の安全性を評価し、治療が完了するまでどれだけの人が治療を継続できるかを目指す。 調査でわかったこと 有害なアルコール使用を減らすための介入の効果を評価した66件のランダム化比較試験を特定した。これらの研究のほとんどは心理社会的介入を評価したものであり（52件）、6件は薬理学的介入のみを評価し、8件は薬理学的介入と心理社会的介入を組み合わせて評価したものであった。 ...

βサラセミア患者に対する骨粗鬆症の治療 論点 βサラセミア患者における骨粗鬆症に対するさまざまな治療法は、どの程度有効かつ安全か？ 背景 骨粗鬆症は、時間とともに骨密度に影響を及ぼし、骨折のリスクを上昇させる。また、βサラセミア（ヘモグロビンの産生が低下する血液疾患）患者に発生する病気の重要な原因となっている。 βサラセミア患者における骨粗鬆症の治療には、ビスフォスフォネート（骨量減少を遅らせる薬剤）、カルシトニン、カルシウム、亜鉛の補給、ヒドロキシ尿素、ホルモン補充療法（HRT）、デノスマブ（骨吸収を抑制して骨密度（BMD）を高める薬剤）、ラネル酸ストロンチウム（骨形成を促進し、骨吸収を阻害する薬剤）などが有効と考えられている。 本レビューの目的は、βサラセミア患者における骨粗鬆症に対する最も効果的な治療法を見つけることである。腰椎、股関節、および手首（手関節）の骨密度（数値が高いほど良好）と、骨折、可動性、生活の質、および治療による有害事象を主要な評価項目とした。本レビューは、過去に発表されたコクランレビューの更新版である。 文献の検索日 本エビデンスは2022年8月4日までの文献検索に基づいている。 研究の特徴 本レビューでは、10歳から78歳の合計298人のβサラセミア患者を治療群にランダムに割り付けた6件の研究が対象となった 。 研究では、ビスフォスフォネート（アレンド...

心肺蘇生時における家族の立ち会い なぜこの問題が重要なのか？ 患者とその親族が、治療の決定に積極的に関与することを望むようになっている。しかし、心肺蘇生時における家族の立ち会い（FPDR）は、立ち会った親族に心的外傷後ストレス障害（PTSD）関連症状を引き起こしたり、医療従事者の妨げとなり、救命救急処置の質を低下させる懸念がある。また、その状況に対する患者の考えや好みが語られないため、患者の守秘義務が侵害される恐れもある。患者、親族、医療従事者の行動は、互いに影響を与える三角形の関係として捉えられるため、それぞれの要求に対するバランスがとられている必要がある。 何を調べようとしたのか？ 心停止、外傷、急性期医療におけるFPDRの効果に関する現在のエビデンスについて調査を行った。 本レビューの主な目的は、親族に対して、その大切な人の心停止、外傷、または急性期医療に立ち会うという選択肢を提供することが、親族のPTSD関連症状の発生に与える影響について調査することである。 第二の目的は、FPDRの提供が、親族の抑うつ、不安、および悲嘆に与える影響、診療時間や医療従事者に対して与える影響、そして、医療の質や患者の生存率に与える影響について調査することである。 何を行ったのか？ 2022年3月22日に、言語による制限なく、医学データベースの検索を行った。また、参考文献を確認し、論文の著者と...

骨盤位胎児（逆子）の回転に対する灸 論点は何か 骨盤位（胎児の臀部が下にある状態）は妊娠中期（第２期）に多くみられる。ほとんどの胎児は陣痛が始まる前に頭が下になるように自身で回転するが、回転しない胎児もみられる。臀部または足が先に出てくる胎児は、出産が困難になる可能性がある。これは母体および胎児に問題を引き起こす可能性があり、胎児は帝王切開で生まれる可能性が高くなる。 灸は中医学の一種で、骨盤位の胎児の回転に有用である可能性がある。それは足小指の経穴の皮膚の近くでアルテメシア（ Artemesia ）という生薬を燃やし温感を生じさせ、子宮に刺激を与えるというものである。この手技は、安全な灸のやり方の訓練を受けた上で妊婦またはその家族や友人が行うことができる。 重要である理由 骨盤位での経膣分娩は、経験豊富な医師や助産師、設備の整った病院であれば可能であり、プライマリーケアの環境以外でも計画外の経膣分娩は起こりうる。しかし、胎児が骨盤位にある女性の経膣分娩をすべての病院で行なえるわけではなく、帝王切開による分娩が計画されることもある。帝王切開には現在および将来の妊娠に対するリスク（危険）があるため、帝王切開を避けたいと考える医療従事者や妊婦は多い。自宅で妊婦やその家族、友人が自分でできる灸治療が、分娩前の頭位回転に役立つかどうかを明らかにしたいと考えた。 得られたエビデンス 灸＋通...